New drug sacituzumab tirumotecan reduces endometrial cancer progression and mortality

An international study demonstrates that the drug sacituzumab tirumotecan (sac-TMT) effectively decreases recurrence and death rates in endometrial cancer patients. The drug works by targeting a protein on tumor cells to deliver a chemical that induces cancer cell death. This development marks a significant advancement in targeted cancer therapies.

Originally published by gnews